United States of America. The manufacturer of levocarnitine (Carnitor: Sigma-Tau) has revised the adverse reaction section of the labelling for the tablet, oral solution and injection formulations to include the following statement regarding the occurrence of seizures in some patients receiving levocarnitine:

“Seizures have been reported to occur in patients with or without pre-existing seizure activity receiving either oral or intravenous levocarnitine. In patients with pre-existing seizure activity, an increase in seizure frequency and/or severity has been reported.”

Reference: “Dear Health Professional” letter from Sigma-Tau Inc., 23 July 1998.
[http://www.fda.gov/medwatch/safety/1998/carnit.htm]